BioSpace News Archive

Entrinsic Bioscience and its licensee Nuvara Therapeutics announces they are one step closer to using RxAA formulations as a therapy for patients with Cystic Fibrosis Class I mutations.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced the presentation of preclinical data for DCC-3116, the Company’s first-in-class ULK kinase inhibitor, in combination with KRASG12C inhibitors in non-small cell lung cancer (NSCLC) models at the American Association for Cancer Research (AACR) Annual Meeting 2022.

MaxCyte, Inc. announced that Amanda Murphy has resigned from her position as Chief Financial Officer, effective as of April 15, 2022, to pursue other interests.

Aziyo Biologics, Inc. announced that the Company’s CanGaroo® Envelope will be highlighted in an upcoming Key Opinion Leader Call hosted by Cowen.

Navidea Biopharmaceuticals, Inc. announced that its Board of Directors has adopted a Section 382 Rights Agreement that is designed to protect the availability of the Company’s net operating loss carryforwards and other tax assets.

Physiotherapy (Physical Therapy), which uses mechanical pressure and motion for remedy is gaining popularity, at a quick tempo because of numerous motives like city life-style, aged population, and company life-style.

IQVIA Holdings Inc. will announce its first-quarter 2022 financial results before the market opens on Wednesday, April 27, 2022.

The surge in research and development activities and technological advancements led to implementation of epigenetics.

Gritstone bio, Inc. delivered three presentations further supporting the potential of its novel vaccine development capabilities and delivery platforms to develop transformational therapeutic cancer vaccines at the 2022 American Association for Cancer Research Annual Meeting.

Adge Pharmaceuticals (“Adge”) continues to advance its rare disease programs in the Rett Syndrome and Osteogenesis imperfecta in support of the regulatory requirements of the US FDA to move its lead asset expeditiously to the clinic.